Skip to main content
OpenTrials
Completed

NCT Number: NCT07322224

Multi-Modal Longevity Protocol Including Autologous Cell-Free Conditioned Media

This pilot study evaluated a multi-modal longevity protocol combining lifestyle optimisation, nutritional supplementation, and autologous cell-free conditioned media derived from peripheral blood-derived pro-regenerative cells (APRC-CM). Fourteen healthy adult participants completed a 17-week programme including baseline and post-intervention biomarker assessments. The primary objective was to characterise changes in biological age using DNA methylation-based epigenetic clocks, PhenoAge and other physiological and biochemical markers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Biological Aging Healthy Aging Longevity

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wellbeing International Foundation

London, W1G 0PG, United Kingdom

About this study

This exploratory study investigated the biological effects of a structured, multi-modal longevity programme that included lifestyle optimisation (nutrition, exercise, sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells cultured ex vivo to produce a pro-regenerative secretome containing soluble factors and extracellular vesicles.

Participants underwent biomarker assessments at baseline and at week 17. Outcomes included measurements of epigenetic biological age, phenotypic age, inflammatory markers, metabolic markers, and other laboratory and physiological variables. The study was conducted in healthy adults and designed as a minimal-risk physiological investigation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 45 years or older
  • Generally good overall health as assessed by the study team
  • Able and willing to provide written informed consent
  • Willing to participate in all components of the study protocol, including lifestyle optimisation, nutritional supplementation, blood collection, and scheduled follow-up visits
  • Able to comply with study procedures for the duration of the intervention and assessments

Exclusion criteria

  • Presence of a major medical condition that, in the opinion of the investigators, could affect participation or safety
  • Any condition requiring hospitalization or emergency medical intervention within the past 12 months
  • Receipt of anti-aging or longevity treatments within the past six months (e.g., intravenous therapies, regenerative or cellular treatments, structured age-reversal programmes)
  • Active infectious disease at enrolment
  • Pregnancy or breastfeeding
  • Use of systemic immunomodulatory, cytotoxic, or investigational treatments in the prior 3 months
  • Any condition or circumstance that, in the judgement of the investigators, may interfere with study participation or data integrity

Treatment and study plan

Multi-Modal Longevity Protocol

Behavioral

The intervention consisted of a structured, multi-modal longevity program that included lifestyle optimization (nutrition, physical activity, and sleep routines), nutritional supplementation, and autologous cell-free conditioned media (APRC-CM). APRC-CM was prepared individually for each participant from peripheral blood-derived pro-regenerative cells and administered as part of a physiologic, minimal-risk exploratory protocol.

Primary outcomes

  1. Change in Epigenetic Biological Age

    Time frame: Baseline and Week 17

    Biological age calculated from DNA methylation profiles using validated epigenetic clock algorithms.

Secondary outcomes

  1. Change in Phenotypic Age

    Time frame: Baseline and Week 17

    Phenotypic age calculated from clinical biomarkers using published phenotypic age algorithms.

Other outcomes

  1. Incidence of Adverse Events

    Time frame: From baseline to Week 17

    Monitoring of any self-reported or observed adverse events throughout the study period. Events were recorded and assessed descriptively.

Sponsors and collaborators

Lead sponsor

BlueBird Age Reversal SA

Industry

Collaborators

  • Wellbeing International Foundation
  • xLongevity

Registry information

Official study title

A Multi-Modal Longevity Protocol Integrating Lifestyle, Supplements, and Autologous Pro-Regenerative Cell-Conditioned Media: A Pilot Study

Important dates

Study start
2024
Primary completion
2024
Study completion
2025
First posted
Jan 7, 2026
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.